Corporate News – Market Performance and Company Overview
Kyverna Therapeutics Inc. (ticker KYTX) closed down 3.31 % in the 24‑hour trading window ending 07:57 AM Central European Time on Thursday, 22 November 2026. The share price was USD 5.84 at the close.
- Shares outstanding: 61.8 million
- Market capitalization: USD 373.5 million
- Volume in last 24 hours: USD 4.8 million worth of shares were traded.
- Month‑to‑date change: The stock has declined 22.24 % since the end of the previous month.
- 200‑day simple moving average: USD 8.19
- 52‑week range: Highest price reached USD 13.67 on 15 December 2025; lowest price was USD 5.61 on 14 October 2026.
24‑Hour Performance of Peer Companies
| Company | Ticker | 24‑hr change | Current price (USD) | Market cap (USD mn) | P/E ratio |
|---|---|---|---|---|---|
| Niocorp Developments | NB | +3.30 % | 3.13 | 441.9 | – |
| First Bank/hamilton NJ | FRBA | –0.95 % | 17.78 | 440.1 | 10.5 |
| Malibu Boats | MBUU | –1.18 % | 21.84 | 440.8 | 257.01 |
| Caleres | CAL | –1.78 % | 12.72 | 445.7 | 8.4 |
| Altimmune | ALT | –3.04 % | 2.23 | 447.4 | – |
Company Profile – Kyverna Therapeutics
Kyverna Therapeutics Inc. is a United States‑based biotechnology company focused on the development of therapies for oncology and immunology indications. The firm is preparing for an initial public offering on the Nasdaq stock exchange scheduled for 8 February 2024. The company’s pipeline includes several candidates that aim to address unmet needs in cancer and immune‑related diseases.
The information presented is based on the most recent publicly available trading data and company disclosures as of 22 November 2026.
